中國心連心化肥(01866.HK)年度淨利潤預增不低於200%
格隆匯1月18日丨中國心連心化肥(01866.HK)公佈,預計截至2021年12月31日止年度,集團淨利潤與去年同期相比增長不低於200%。
集團淨利潤增加主要是由於:1、集團藉助化肥主業在行業的領先優勢,帶動各類化工產品業績提升,"肥化並舉"利於產業鏈協同發展,促進業績穩固增長;2、利用基地化佈局,充分發揮柔性調節,確保資源利用最大化,不斷優化升級生產技術,加強科技創新,強化"低成本+差異化"優勢,實現集團高質量發展;3、國際能源及糧食價格上漲,推動化肥及化工品價格提升,使集團主要產品三聚氰胺、糠醇及甲醇受益明顯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.